Table 1

Relative Fitness of Mutant and Wild-type UL97 Viruses after Initiation of Ganciclovir Therapy (Patients 1–10) or HPMPC Therapy (Patients 11–13)

PatientMutationRelative fitness gain
Mutant vs. wild-type(%)
1L595F3.9
2L595F5.6
3L595F5.3
4L595S9.0
5L595S8.0
6M460V3.7
7M460I4.8
8H520Q5.0
9A594V + M460I2.6
10L595F + M460I7.5
Wild-type vs. mutant
11L595S3.5
12L595F5.6
13M460I + L595F12.8